Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 15/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.41 |
| ▸ | PDE4A | P27815 | 14/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.41 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.38 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022392 | 0.90 | PDE4D (0.52) | PDE4DPDE4BPDE4APDE4CKCNMA1 | |
| SCHEMBL4035506 | 0.85 | PDE4D (0.47) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5026648 | 0.84 | PDE4B (0.51) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL4025932 | 0.84 | PDE4D (0.59) | PDE4DPDE4BPDE4APDE4CMAPT | |
| SCHEMBL5016448 | 0.82 | PDE4D (0.61) | PDE4DPDE4BPDE4APDE4CPDE11A | |
| SCHEMBL5022806 | 0.78 | TBK1 (0.47) | PDE4DPDE4BPDE4APDE4CKCNMA1 | |
| SCHEMBL4147671 | 0.76 | PDE4D (0.74) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5026451 | 0.75 | PDE4B (0.53) | PDE4DPDE4BPDE4APDE4CMAPT | |
| SCHEMBL5017994 | 0.75 | PDE4B (0.43) | PDE4DPDE4BPDE4APDE4CMAPT | |
| SCHEMBL5018018 | 0.74 | PDE4D (0.43) | PDE4DPDE4BPDE4APDE4CKCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554262-B1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD (IN) | 2007-12-05 | — | — | EP | claimed |
| US-7238725-B2 | Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-07-03 | — | — | US | claimed |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2006-08-10 | — | — | US | claimed |
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-06-19 | — | — | US | disclosed |
| EP-1554262-B1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD (IN) | 2007-12-05 | — | — | EP | disclosed |
| US-7238725-B2 | Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-07-03 | — | — | US | disclosed |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LTC4S, TSLP, GPR119 | PDE4D 2321/4885PDE4B 1684/4885PDE4A 1723/4885 |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | LTC4S, TSLP, GPR119 | PDE4D 2321/4885PDE4B 1684/4885PDE4A 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.